Region-specific glutamate changes in patients with unipolar depression

Journal of Psychiatric Research

Volumn 46, Issue 8, 2012, Pages 1059-1065

  Grimm, Simone ^a,b,c   Luborzewski, Alexander ^a   Schubert, Florian ^d   Merkl, Angela ^a,b   Kronenberg, Golo ^a   Colla, Michael ^a   Heuser, Isabella ^a   Bajbouj, Malek ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^d PHYSIKALISCH TECHNISCHE BUNDESANSTALT   (Germany)

Author keywords

Cingulate cortex; Depression; DLPFC; Glutamate; Response prediction

Indexed keywords

ANTIDEPRESSANT AGENT; GLUTAMIC ACID;

ADULT; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREFRONTAL CORTEX; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84863492257     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.04.018     Document Type: Article

References (60)

1. Altamura C.A., Mauri M.C., Ferrara A., Moro A.R., D'Andrea G., Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. American Journal of Psychiatry 1993, 150(11):1731-1733.
2. An X., Bandler R., Ongur D., Price J.L. Prefrontal cortical projections to longitudinal columns in the midbrain periaqueductal gray in macaque monkeys. Journal of Comparative Neurology 1998, 401(4):455-479.
3. Auer D.P., Putz B., Kraft E., Lipinski B., Schill J., Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry 2000, 47(4):305-313.
4. Batra N.A., Seres-Mailo J., Hanstock C., Seres P., Khudabux J., Bellavance F., et al. Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biological Psychiatry 2008, 63(12):1178-1184.
5. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2008, 33(9):2175-2186.
6. Bhagwagar Z., Wylezinska M., Jezzard P., Evans J., Ashworth F., Sule A., et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biological Psychiatry 2007, 61(6):806-812.
7. Bonvento G., Sibson N., Pellerin L. Does glutamate image your thoughts?. Trends in Neurosciences 2002, 25(7):359-364.
8. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry 1999, 60(2):79-88.
9. Chiba T., Kayahara T., Nakano K. Efferent projections of infralimbic and prelimbic areas of the medial prefrontal cortex in the Japanese monkey, Macaca fuscata. Brain Research 2001, 888(1):83-101.
10. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proceedings of the National Academy of Sciences USA 2005, 102(43):15653-15658.
11. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cerebral Cortex 2002, 12(4):386-394.
12. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Archives of General Psychiatry 2001, 58(6):545-553.
13. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Archives of General Psychiatry 2008, 65(2):154-164.
14. Elster C., Schubert F., Link A., Walzel M., Seifert F., Rinneberg H. Quantitative magnetic resonance spectroscopy: semi-parametric modeling and determination of uncertainties. Magnetic Resonance in Medicine 2005, 53(6):1288-1296.
15. Freedman L.J., Insel T.R., Smith Y. Subcortical projections of area 25 (subgenual cortex) of the macaque monkey. Journal of Comparative Neurology 2000, 421(2):172-188.
16. Gao S.F., Bao A.M. Corticotropin-releasing hormone, glutamate, and gamma-aminobutyric acid in depression. Neuroscientist 2011, 17(1):124-144.
17. Gibbons A.S., Brooks L., Scarr E., Dean B. AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder. Journal of Affective Disorders 2011.
18. Goldapple K., Segal Z., Garson C., Lau M., Bieling P., Kennedy S., et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry 2004, 61(1):34-41.
19. Goldstein M., Brendel G., Tuescher O., Pan H., Epstein J., Beutel M., et al. Neural substrates of the interaction of emotional stimulus processing and motor inhibitory control: an emotional linguistic go/no-go fMRI study. Neuroimage 2007, 36(3):1026-1040.
20. Grimm S., Beck J., Schuepbach D., Hell D., Boesiger P., Bermpohl F., et al. Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. Biological Psychiatry 2008, 63(4):369-376.
21. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960, 23:56-62.
22. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry 2007, 62(11):1310-1316.
23. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of General Psychiatry 2007, 64(2):193-200.
24. Johansen-Berg H., Gutman D.A., Behrens T.E., Matthews P.M., Rushworth M.F., Katz E., et al. Anatomical connectivity of the subgenual cingulate region targeted with deep brain stimulation for treatment-resistant depression. Cerebral Cortex 2008, 18(6):1374-1383.
25. Kim J.S., Schmid-Burgk W., Claus D., Kornhuber H.H. Increased serum glutamate in depressed patients. Archiv fur Psychiatrie und Nervenkrankheiten 1982, 232(4):299-304.
26. Krystal J.H. Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: new opportunities for synergy with psychotherapy. Biological Psychiatry 2007, 62(8):833-834.
27. Luborzewski A., Schubert F., Seifert F., Danker-Hopfe H., Brakemeier E.L., Schlattmann P., et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. Journal of Psychiatric Research 2007, 41(7):606-615.
28. Luykx J.J., Laban K.G., van den Heuvel M.P., Boks M.P., Mandl R.C., Kahn R.S., et al. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings. Neuroscience & Biobehavioral Reviews 2012, 36(1):198-205.
29. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33(9):2080-2092.
30. Mauri M.C., Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998, 37(3):124-129.
31. Mayberg H.S. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clinics of North America 2003, 13(4):805-815.
32. Mayberg H.S., Liotti M., Brannan S.K., McGinnis S., Mahurin R.K., Jerabek P.A., et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. American Journal of Psychiatry 1999, 156(5):675-682.
33. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45(5):651-660.
34. Meloni D., Gambarana C., De Montis M.G., Dal Pra P., Taddei I., Tagliamonte A. Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacology, Biochemistry, and Behavior 1993, 46(2):423-426.
35. Merkl A., Schubert F., Quante A., Luborzewski A., Brakemeier E.L., Grimm S., et al. Abnormal cingulate and prefrontal cortical neurochemistry in major depression after electroconvulsive therapy. Biological Psychiatry 2011, 69(8):772-779.
36. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30(6):1155-1158.
37. Nery F.G., Stanley J.A., Chen H.H., Hatch J.P., Nicoletti M.A., Monkul E.S., et al. Normal metabolite levels in the left dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: a single voxel (1)H spectroscopy study. Psychiatry Research 2009, 174(3):177-183.
38. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proceedings of the National Academy of Sciences USA 1998, 95(22):13290-13295.
39. Palomero-Gallagher N., Vogt B.A., Schleicher A., Mayberg H.S., Zilles K. Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model. Human Brain Mapping 2009, 30(8):2336-2355.
40. Phan K.L., Wager T., Taylor S.F., Liberzon I. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage 2002, 16(2):331-348.
41. Phillips M.L., Drevets W.C., Rauch S.L., Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biological Psychiatry 2003, 54(5):515-528.
42. Portella M.J., de Diego-Adelino J., Gomez-Anson B., Morgan-Ferrando R., Vives Y., Puigdemont D., et al. Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients. Journal of Psychiatric Research 2011, 45(4):427-434.
43. Rajkowska G., Halaris A., Selemon L.D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biological Psychiatry 2001, 49(9):741-752.
44. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biological Psychiatry 1999, 45(9):1085-1098.
45. Ressler K.J., Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nature Neuroscience 2007, 10(9):1116-1124.
46. Salvadore G., van der Veen J.W., Zhang Y., Marenco S., Machado-Vieira R., Baumann J., et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 2011, 1-10.
47. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry 2004, 61(7):705-713.
48. Sanacora G., Rothman D.L., Mason G., Krystal J.H. Clinical studies implementing glutamate neurotransmission in mood disorders. Annals of the New York Academy of Sciences 2003, 1003:292-308.
49. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7(5):426-437.
50. Schubert F., Gallinat J., Seifert F., Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 2004, 21(4):1762-1771.
51. Tokita K., Yamaji T., Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacology Biochemistry & Behavior 2011.
52. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophrenia Research 2004, 67(2-3):269-275.
53. Vogt B.A., Berger G.R., Derbyshire S.W. Structural and functional dichotomy of human midcingulate cortex. European Journal of Neuroscience 2003, 18(11):3134-3144.
54. Vogt B.A., Vogt L., Farber N.B., Bush G. Architecture and neurocytology of monkey cingulate gyrus. Journal of Comparative Neurology 2005, 485(3):218-239.
55. Vollenweider F.X., Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience 2010, 11(9):642-651.
56. Yilmaz A., Schulz D., Aksoy A., Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacology Biochemistry & Behavior 2002, 71(1-2):341-344.
57. Yuksel C., Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biological Psychiatry 2010, 68(9):785-794.
58. Zarate C.A., Payne J.L., Quiroz J., Sporn J., Denicoff K.K., Luckenbaugh D., et al. An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry 2004, 161(1):171-174.
59. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63(8):856-864.
60. Zarate C.A., Quiroz J., Payne J., Manji H.K. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacology Bulletin 2002, 36(4):35-83.